EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells

Roberta Vacca, Lucrezia Della Volpe, Nicolò Gualandi, Kohei Shiroshita, Edoardo Carsana, Kety Giannetti, Chiara Gaddoni, Fabrizio Benedicenti, Barbara Gega, Sergio Arévalo, Parinaz Zarghamian, Stefano Beretta und 9 weitere

Molecular Therapy · 2026-11 · 34 (11) · 6234-6242

DOI: 10.1016/j.ymthe.2026.09.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Roberta Vacca und 20 weiteren Autor:innen. Beteiligte Einrichtung: San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele Un…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, p38 Mitogen-Activated Protein Kinases, Gene Editing, Protein Kinase Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ex vivo genome editing of hematopoietic stem and progenitor cells (HSPCs) holds significant therapeutic potential but remains constrained by genotoxic risks associated with nuclease-induced DNA double-strand breaks, DNA donor template delivery and sensing, and proliferation-induced stress during ex vivo manipulation. These processes can lead to chromosomal instability, large on-target deletions, donor mis-integration, off-target events, and impaired long-term stem cell function, raising safety concerns for clinical translation. Here, we evaluate the impact of transient p38 MAPK inhibition on genomic integrity during clinically relevant CRISPR-Cas9 editing and show that this intervention attenuates ex vivo culture-associated stress without increasing detectable genotoxic outcomes. Comprehensive genotoxicity analyses, including quantification of large on-target deletions, adeno-associated viral vector mis-integration, and CAST-seq mapping of translocations, reveal no measurable differences in gene editing-associated structural alterations upon p38 MAPK inhibition, while micronuclei were significantly reduced. Importantly, long-term xenotransplantation followed by whole-exome sequencing shows that p38i-treated HSPCs display a reduced mutational burden without evidence of increased genomic alterations. Collectively, these findings identify transient p38 MAPK inhibition as a strategy to improve the quality and long-term fitness of gene-edited HSPCs without detectable adverse effects on the genome editing outcomes, supporting its further evaluation as a refinement to clinically relevant CRISPR-Cas9 editing workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cellsp38 Mitogen-Activated Protein KinasesGene EditingProtein Kinase InhibitorsHumansAnimalsCRISPR-Cas SystemsMice

Stichwörter der Autor:innen

DNA damage responsegene editing and homology-directed repairgene therapygenome integrityhematopoietic stem cellsp38 MAPK

Substanzen

p38 Mitogen-Activated Protein KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy.
  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Japan Society for the Promotion of Science, Tokyo 102-0083, Japan.
  • Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency (CCI), Faculty of Medicine, University of Freiburg, 79106 Freibu…
  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Institute for Genetic and Biomedical Research, National Research Council, 20090 Milan, Italy.
  • University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, 20132 Milan, Italy.

Förderung

  • European Research Council

Zitieren

APA

Vacca, R., Della Volpe, L., Gualandi, N., Shiroshita, K., Carsana, E., Giannetti, K., Gaddoni, C., Benedicenti, F., Gega, B., Arévalo, S., Zarghamian, P., Beretta, S., Castiello, M. C., Brombin, C., Canarutto, D., Merelli, I., Cathomen, T., Montini, E., Villa, A., …, & Di Micco, R. (2026). p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells. Molecular Therapy, 34(11), 6234-6242. https://doi.org/10.1016/j.ymthe.2026.09.024

Vancouver

Vacca R, Della Volpe L, Gualandi N, Shiroshita K, Carsana E, Giannetti K, et al. p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells. Molecular Therapy. 2026;34(11):6234-6242. doi:10.1016/j.ymthe.2026.09.024

BibTeX
@article{Vacca2026,
  author = {Vacca, Roberta and Della Volpe, Lucrezia and Gualandi, Nicolò and Shiroshita, Kohei and Carsana, Edoardo and Giannetti, Kety and Gaddoni, Chiara and Benedicenti, Fabrizio and Gega, Barbara and Arévalo, Sergio and Zarghamian, Parinaz and Beretta, Stefano and Castiello, Maria Carmina and Brombin, Chiara and Canarutto, Daniele and Merelli, Ivan and Cathomen, Toni and Montini, Eugenio and Villa, Anna and Naldini, Luigi and Di Micco, Raffaella},
  title = {p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {6234--6242},
  doi = {10.1016/j.ymthe.2026.09.024}
}
Kostenlos starten →